CAC2 Childhood Cancer Community News Digest (January 8-14)

Assorted News from the Last Week:

The Coalition Against Childhood Cancer (CAC2) takes great pride in introducing its groundbreaking CAC2 Survivorship Toolkit.

Scientists found that two common biomarkers could predict cardiomyopathy that is otherwise undetected by conventional screenings in childhood cancer survivors.

Michael Strahan’s 19-year-old daughter Isabella is battling a malignant brain tumor known as medulloblastoma, the “Good Morning America” co-anchor and his daughter shared Thursday.

Cancer specialists remain baffled about the cause(s) of an alarming increase in cancer among younger adults. (gated)

The use of low-dose carvedilol did not significantly improve certain cardiac measures of heart failure risk in long-term survivors of childhood cancer exposed to anthracycline.

Insurance doesn’t always cover hearing aids for kids.

U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) New Drug Therapy Approvals report for 2023.

Join us in celebrating the successful collaboration between Nicole Scobie (Zoe4Life) and Nick Bird (Solving Kids’ Cancer-UK) who contributed to this Journal of Clinical Oncology Commentary calling for a new regulatory approach for developing CAR-T therapies for pediatric cancer patients.

Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumor drugs as well as chemotherapy.

Scientists have developed 3D mini-organs from human fetal brain tissue that self-organize in vitro. These lab-grown organoids open up a brand-new way of studying how the brain develops. They also offer a valuable means to study the development and treatment of diseases related to brain development, including brain tumors.

Correlating food and nutritional patterns with cancers in the pediatric oncology population at two specialized hospitals in Tanzania

Upcoming Webinars, Online Opportunities, and Meetings:

Join CCLG Research Talks on January 17 at 2:oo pm ET to hear “How can leukaemia treatment affect a child’s brain?”  For information and to register.

Healing Hearts was created by grieving parents who needed a haven of love and comfort along with the hope of healing. Together, we support each other in creating a life worth living, for and with our children. Healing Hearts is for Osteosarcoma Bereaved families only and meets once a month on Wednesdays from 7- 8PM ET on the following dates:  January 31, February 28, March 27, and April 24.  For information and to register.

MIB Agents osTEAo podcast drops January 18.  For information and links.

Free webinar hosted by NCI:  “Navigating St. Jude’s PeCan v2 & Survivorship Data Sharing Tools” on January 23 at 1:00–2:00 p.m. ET.  Register here.

Dr. Andy Livingston will offer an MIBAgents webinar on OsteoBites to discuss the background and scientific rationale for combining immunotherapy with cabozantinib in teens and young adults with osteosarcoma and provide information about the ongoing TACOS study at 3:00 ET on January 25.    For information and to register.

Webinar on the Individual Education Program (IEP) document, its development, the breakdown of each section and understand how the document will support a student, 6:00-8:30 pm ET, January 31.  For information and to register.

ACCELERATE Annual Conference 2024 on February 8 & 9 in Brussels. Learn about the most recent successes in paediatric oncology drug development worldwide, the latest regulatory updates in Europe and North America and more.  For information and to register.

Austin Hatcher Foundation Bubbles of Fun 5K, 10K, and 1-Mile Fun Run, February 10 at Tennessee Riverpark.  For information and to register.

Alliance for Childhood Cancer has announce that Action Days 2024 will take place in Washington, DC from February 13-14, 2024. Registration will open in mid-December.  Click for information.

FDA’s Rare Disease Day will be on Friday, March 1, 2024, and registration is open for this virtual event. This year’s Rare Disease Day is dedicated to patients and health care professionals.

Recent Recordings:

In this video, Stephen M. Ansell, MD, PhD, discussed updated study results showing an advantage of nivolumab-chemo over brentuximab vedotin-chemo in both younger and older Hodgkin Lymphoma patients.

Take Action:

The 2024 ASCO-Sponsored Patient Advocacy Booth will provide 50 complimentary exhibits to patient advocacy organizations at the ASCO Annual Meeting. The booth provides a venue where participants can display materials and where meeting attendees and patient advocates can meet, interact, and exchange information. Applications will be accepted between Monday, February 5 at 10:00 AM (ET) and Monday, February 12 at 5:00 PM (ET). Once the application period opens, the link to the application will be available on Cancer.Net.

The Childhood Cancer Data Initiative (CCDI) is seeking input to assist NCI in using electronic health record (EHR) data to accelerate progress in childhood cancer research. You are invited to respond to our latest Request for Information (RFI) to share your capabilities in automated EHR data entry and extraction. Submissions will be accepted until February 29, 2024.  Submit a response to share your tools, clinical workflows, and approaches for entering and extracting EHR data in a structured format. You may also respond with insights on how existing tools for data capturing, extraction, and transformation in adult cancer research can be used to support childhood and rare cancer research. Feel free to reach out to Subhashini Jagu with questions.

Triage Cancer launched Triage Health, a program that provides free education on the legal and practical issues related to navigating a chronic or serious medical condition. Learn more.

The White House asks for our community to stay tuned to for updates – and stay involved by sharing new actions and impactful stories and ideas to inspire others and help end cancer as we know it.


Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.

This field is for validation purposes and should be left unchanged.

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.